FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 125 filers reported holding FATE THERAPEUTICS INC in Q4 2018. The put-call ratio across all filers is 0.76 and the average weighting 0.6%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2021 | $10,879,000 | +1019.2% | 125,350 | +962.7% | 1.35% | +977.6% |
Q1 2021 | $972,000 | +196.3% | 11,795 | -20.2% | 0.12% | +15.7% |
Q1 2020 | $328,000 | -83.1% | 14,780 | -88.2% | 0.11% | -82.9% |
Q3 2019 | $1,942,000 | +55.2% | 125,060 | +103.0% | 0.63% | +55.5% |
Q2 2019 | $1,251,000 | -60.2% | 61,615 | -65.5% | 0.41% | -63.4% |
Q1 2019 | $3,141,000 | +71.5% | 178,790 | +25.2% | 1.11% | +50.4% |
Q4 2018 | $1,832,000 | – | 142,760 | – | 0.74% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 3,379,064 | $7,163,616 | 2.64% |
Redmile Group, LLC | 13,124,427 | $27,823,785 | 1.32% |
Monaco Asset Management SAM | 1,847,944 | $3,917,641 | 1.16% |
Casdin Capital, LLC | 2,050,000 | $4,346,000 | 0.48% |
TANG CAPITAL MANAGEMENT LLC | 700,000 | $1,484,000 | 0.21% |
GCM Grosvenor Holdings, LLC | 495,916 | $1,051,342 | 0.21% |
Nebula Research & Development LLC | 163,617 | $346,868 | 0.18% |
Bellevue Group AG | 4,851,579 | $10,285,347 | 0.17% |
Bruce & Co., Inc. | 200,000 | $424,000 | 0.14% |
XTX Topco Ltd | 192,920 | $408,990 | 0.07% |